Treatment comparison in rheumatoid arthritis: Head-to-head trials and innovative study designs

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Favalli, Ennio Giulio ^a   Bugatti, Serena ^b   Biggioggero, Martina ^a   Caporali, Roberto ^b  

^a ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; AURANOFIN; AUROTHIOMALATE; AZATHIOPRINE; BIOLOGICAL MARKER; BIOLOGICAL PRODUCT; BIOSIMILAR AGENT; C REACTIVE PROTEIN; CELECOXIB; CERTOLIZUMAB PEGOL; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NEW DRUG; PARACETAMOL; PLACEBO; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT;

BIOLOGICAL THERAPY; CLINICAL PRACTICE; CLUSTER ANALYSIS; COMPARATIVE EFFECTIVENESS; DAS28; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROCYTE SEDIMENTATION RATE; EXTERNAL VALIDITY; FOLLOW UP; HUMAN; INTERNAL VALIDITY; JOINT RADIOGRAPHY; META ANALYSIS; MONOTHERAPY; MULTICENTER STUDY (TOPIC); OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; STUDY DESIGN; TREATMENT DURATION; ARTHRITIS, RHEUMATOID; METHODOLOGY; PATHOLOGY; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 84900013361     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/831603     Document Type: Review

References (129)

1. Black R. L., O'Brien W. M., Vanscott E. J., Auerbach R., Eisen A. Z., Bunim J. J., Methotrexate therapy in psoriatic arthritis, double-blind study on 21 patients. Journal of the American Medical Association 1964 189 743 747
2. Weinblatt M. E., Coblyn J. S., Fox D. A., Efficacy of low-dose methotrexate in rheumatoid arthritis. The New England Journal of Medicine 1985 312 13 818 822 2-s2.0-0021923633
3. Williams H. J., Willkens R. F., Samuelson C. O. Jr., Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis and Rheumatism 1985 28 7 721 730 2-s2.0-0021794435
4. Feldmann M., Brennan F. M., Maini R. N., Role of cytokines in rheumatoid arthritis. Annual Review of Immunology 1996 14 397 440 2-s2.0-0029876121 10.1146/annurev.immunol.14.1.397
5. Linsley P. S., Nadler S. G., The clinical utility of inhibiting CD28-mediated costimulation. Immunological Reviews 2009 229 1 307 321 2-s2.0-65349185047 10.1111/j.1600-065X.2009.00780.x
6. Caporali R., Bugatti S., Cavagna L., Antivalle M., Sarzi-Puttini P., Modulating the co-stimulatory signal for T cell activation in rheumatoid arthritis: could it be the first step of the treatment? Autoimmunity Reviews 2014 13 1 49 53 10.1016/j.autrev.2013.06.008
7. Bugatti S., Codullo V., Caporali R., Montecucco C., B cells in rheumatoid arthritis. Autoimmunity Reviews 2007 7 2 137 142 2-s2.0-36148969711 10.1016/j.autrev.2007.02.017
8. Dörner T., Radbruch A., Burmester G. R., B-cell-directed therapies for autoimmune disease. Nature Reviews Rheumatology 2009 5 8 433 441 2-s2.0-73349131124
9. Fonseca J. E., Santos M. J., Canhão H., Choy E., Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmunity Reviews 2009 8 7 538 542 2-s2.0-67349104400 10.1016/j.autrev.2009.01.012
10. Tanaka T., Narazaki M., Kishimoto T., Therapeutic targeting of the interleukin-6 receptor. Annual Review of Pharmacology and Toxicology 2012 52 199 219 2-s2.0-84555200149 10.1146/annurev-pharmtox-010611-134715
11. FDA Guidance for Industry,. Clinical Development Programs for Drugs, Devices, and Biological Products for the Treatment of Rheumatoid Arthritis, http://www.fda.gov/CDER/GUIDANCE/1208fnl.htm
12. European Medicines Agency-scientific guidelines, http://www.emea.europa. eu/htms/human/humanguidelines/efficacy.htm
13. Westhovens R., Robles M., Ximenes A. C., Nayiager S., Wollenhaupt J., Durez P., Gomez-Reino J., Grassi W., Haraoui B., Shergy W., Park S.-H., Genant H., Peterfy C., Becker J.-C., Covucci A., Helfrick R., Bathon J., Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Annals of the Rheumatic Diseases 2009 68 12 1870 1877 2-s2.0-65349176911 10.1136/ard.2008.101121
14. Breedveld F. C., Weisman M. H., Kavanaugh A. F., Cohen S. B., Pavelka K., Van Vollenhoven R., Sharp J., Perez J. L., Spencer-Green G. T., The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis and Rheumatism 2006 54 1 26 37 2-s2.0-31044442965 10.1002/art.21519
15. Kavanaugh A., Fleischmann R. M., Emery P., Kupper H., Redden L., Guerette B., Santra S., Smolen J. S., Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Annals of the Rheumatic Diseases 2013 72 1 64 71 2-s2.0-84860507750 10.1136/annrheumdis-2011-201247
16. Bathon J. M., Martin R. W., Fleischmann R. M., Tesser J. R., Schiff M. H., Keystone E. C., Genovese M. C., Wasko M. C., Moreland L. W., Weaver A. L., Markenson J., Finck B. K., A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. The New England Journal of Medicine 2000 343 22 1586 1593 2-s2.0-0034735827 10.1056/NEJM200011303432201
17. Emery P., Breedveld F. C., Hall S., Durez P., Chang D. J., Robertson D., Singh A., Pedersen R. D., Koenig A. S., Freundlich B., Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. The Lancet 2008 372 9636 375 382 2-s2.0-48149100741 10.1016/S0140-6736(08)61000-4
18. Emery P., Fleischmann R. M., Moreland L. W., Hsia E. C., Strusberg I., Durez P., Nash P., Amante E. J. B., Churchill M., Park W., Pons-Estel B. A., Doyle M. K., Visvanathan S., Xu W., Rahman M. U., Golimumab, a human anti-tumor necrosis factor monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis and Rheumatism 2009 60 8 2272 2283 2-s2.0-68049099274 10.1002/art.24638
19. St.Clair E. W., van der Heijde D. M. F. M., Smolen J. S., Maini R. N., Bathon J. M., Emery P., Keystone E., Schiff M., Kalden J. R., Wang B., DeWoody K., Weiss R., Baker D., Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis and Rheumatism 2004 50 11 3432 3443 2-s2.0-8444239359 10.1002/art.20568
20. Tak P. P., Rigby W. F., Rubbert-Roth A., Peterfy C. G., Van Vollenhoven R. F., Stohl W. S. W., Hessey E., Chen A., Tyrrell H., Shaw T. M., Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Annals of the Rheumatic Diseases 2011 70 1 39 46 2-s2.0-78650645377 10.1136/ard.2010.137703
21. Kremer J. M., Genant H. K., Moreland L. W., Russell A. S., Emery P., Abud-Mendoza C., Szechinski J., Li T., Ge Z., Becker J.-C., Westhovens R., Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Annals of Internal Medicine 2006 144 12 865 876 2-s2.0-33745291091
22. Schiff M., Keiserman M., Codding C., Songcharoen S., Berman A., Nayiager S., Saldate C., Li T., Aranda R., Becker J.-C., Lin C., Cornet P. L. N., Dougados M., Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Annals of the Rheumatic Diseases 2008 67 8 1096 1103 2-s2.0-47949106400 10.1136/ard.2007.080002
23. Weinblatt M. E., Keystone E. C., Furst D. E., Moreland L. W., Weisman M. H., Birbara C. A., Teoh L. A., Fischkoff S. A., Chartash E. K., Adalimumab, a fully human anti-tumor necrosis factor monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis and Rheumatism 2003 48 1 35 45 2-s2.0-0037231533 10.1002/art.10697
24. Keystone E. C., Kavanaugh A. F., Sharp J. T., Tannenbaum H., Hua Y., Teoh L. S., Fischkoff S. A., Chartash E. K., Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis and Rheumatism 2004 50 5 1400 1411 2-s2.0-2342658406 10.1002/art.20217
25. Keystone E., van der Heijde D., Mason D. Jr., Landewé R., Van Vollenhoven R., Combe B., Emery P., Strand V., Mease P., Desai C., Pavelka K., Ionescu L., Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis and Rheumatism 2008 58 11 3319 3329 2-s2.0-55849112632 10.1002/art.23964
26. Smolen J., Landewé R. B., Mease P., Brzezicki J., Mason D., Luijtens K., Van Vollenhoven R. F., Kavanaugh A., Schiff M., Burmester G. R., Strand V., Vencovský J., Van Der Heijde D., Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Annals of the Rheumatic Diseases 2009 68 6 797 804 2-s2.0-67449124634 10.1136/ard.2008.101659
27. Fleischmann R., Vencovsky J., van Vollenhoven R. F., Borenstein D., Box J., Coteur G., Goel N., Brezinschek H.-P., Innes A., Strand V., Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Annals of the Rheumatic Diseases 2009 68 6 805 811 2-s2.0-67449123606 10.1136/ard.2008.099291
28. Weinblatt M. E., Kremer J. M., Bankhurst A. D., Bulpitt K. J., Fleischmann R. M., Fox R. I., Jackson C. G., Lange M., Burge D. J., A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. The New England Journal of Medicine 1999 340 4 253 259 2-s2.0-0033611472 10.1056/ NEJM199901283400401
29. Klareskog L., van der Heijde D., de Jager J. P., Gough A., Kalden J., Malaise M., Martín Mola E., Pavelka K., Sany J., Settas L., Wajdula J., Pedersen R., Fatenejad S., Sanda M., Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. The Lancet 2004 363 9410 675 681 2-s2.0-10744223002 10.1016/S0140-6736(04)15640-7
30. van Riel P. L. C. M., Taggart A. J., Sany J., Gaubitz M., Nab H. W., Pedersen R., Freundlich B., MacPeek D., Efficacy and safely of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study. Annals of the Rheumatic Diseases 2006 65 11 1478 1483 2-s2.0-33750356014 10.1136/ard.2005.043299
31. Keystone E. C., Genovese M. C., Klareskog L., Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Annals of the Rheumatic Diseases 2009 68 6 789 796 2-s2.0-78650633890 10.1136/ard.2008.099010corr1
32. Maini R., St Clair E. W., Breedveld F., Furst D., Kalden J., Weisman M., Smolen J., Emery P., Harriman G., Feldmann M., Lipsky P., Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. The Lancet 1999 354 9194 1932 1939 2-s2.0-0033524159 10.1016/S0140-6736(99)05246-0
33. Emery P., Fleischmann R., Filipowicz-Sosnowska A., Schechtman J., Szczepanski L., Kavanaugh A., Racewicz A. J., Van Vollenhoven R. F., Li N. F., Agarwal S., Hessey E. W., Shaw T. M., The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis and Rheumatism 2006 54 5 1390 1400 2-s2.0-33646483031 10.1002/art.21778
34. Emery P., Deodhar A., Rigby W. F., Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Annals of the Rheumatic Diseases 2010 69 9 1629 1635 10.1136/ard.2009.119933
35. Rubbert-Roth A., Tak P. P., Zerbini C., Tremblay J.-L., Carreño L., Armstrong G., Collinson N., Shaw T. M., Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR). Rheumatology 2010 49 9 1683 1693 2-s2.0-77955738274 10.1093/rheumatology/keq116
36. Smolen J. S., Beaulieu A., Rubbert-Roth A., Ramos-Remus C., Rovensky J., Alecock E., Woodworth T., Alten R., Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. The Lancet 2008 371 9617 987 997 2-s2.0-40749114497 10.1016/S0140-6736(08)60453-5
37. Kremer J. M., Blanco R., Brzosko M., Burgos-Vargas R., Halland A.-M., Vernon E., Ambs P., Fleischmann R., Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis and Rheumatism 2011 63 3 609 621 2-s2.0-79953680176 10.1002/art.30158
38. Genovese M. C., McKay J. D., Nasonov E. L., Mysler E. F., Da Silva N. A., Alecock E., Woodworth T., Gomez-Reino J. J., Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis and Rheumatism 2008 58 10 2968 2980 2-s2.0-54949150604 10.1002/art.23940
39. Nishimoto N., Yoshizaki K., Miyasaka N., Yamamoto K., Kawai S., Takeuchi T., Hashimoto J., Azuma J., Kishimoto T., Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis and Rheumatism 2004 50 6 1761 1769 2-s2.0-2642558925 10.1002/art.20303
40. Yazici Y., Curtis J. R., Ince A., Baraf H., Malamet R. L., Teng L. L., Kavanaugh A., Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Annals of the Rheumatic Diseases 2012 71 2 198 205 2-s2.0-84855351178 10.1136/ard.2010.148700
41. Genovese M. C., Becker J.-C., Schiff M., Luggen M., Sherrer Y., Kremer J., Birbara C., Box J., Natarajan K., Nuamah I., Li T., Aranda R., Hagerty D. T., Dougados M., Abatacept for rheumatoid arthritis refractory to tumor necrosis factor inhibition. The New England Journal of Medicine 2005 353 11 1114 1123 2-s2.0-24944498854 10.1056/NEJMoa050524
42. Smolen J. S., Kay J., Doyle M. K., Landewé R., Matteson E. L., Wollenhaupt J., Gaylis N., Murphy F. T., Neal J. S., Zhou Y., Visvanathan S., Hsia E. C., Rahman M. U., Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. The Lancet 2009 374 9685 210 221 2-s2.0-67650379733 10.1016/S0140-6736(09)60506-7
43. Furst D. E., Gaylis N., Bray V., Olech E., Yocum D., Ritter J., Weisman M., Wallace D. J., Crues J., Khanna D., Eckel G., Yeilding N., Callegari P., Visvanathan S., Rojas J., Hegedus R., George L., Mamun K., Gilmer K., Troum O., Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Annals of the Rheumatic Diseases 2007 66 7 893 899 2-s2.0-34347225530 10.1136/ard.2006.068304
44. Cohen S. B., Emery P., Greenwald M. W., Dougados M., Furie R. A., Genovese M. C., Keystone E. C., Loveless J. E., Burmester G.-R., Cravets M. W., Hessey E. W., Shaw T., Totoritis M. C., Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis and Rheumatism 2006 54 9 2793 2806 2-s2.0-33746961890 10.1002/art.22025
45. Emery P., Keystone E., Tony H. P., Cantagrel A., van Vollenhoven R., Sanchez A., IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Annals of the Rheumatic Diseases 2009 68 2 296 2-s2.0-58849108578
46. Marchesoni A., Zaccara E., Gorla R., Bazzani C., Sarzi-Puttini P., Atzeni F., Caporali R., Bobbio-Pallavicini F., Favalli E. G., TNF- antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Annals of the New York Academy of Sciences 2009 1173 837 846 2-s2.0-70049109275 10.1111/j.1749-6632.2009.04621.x
47. Pallavicini F. B., Caporali R., Sarzi-Puttini P., Atzeni F., Bazzani C., Gorla R., Marchesoni A., Favalli E. G., Montecucco C., Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry. Autoimmunity Reviews 2010 9 3 175 180 2-s2.0-72449154112 10.1016/j.autrev.2009. 07.006
48. Caporali R., Bobbio-Pallavicini F., Atzeni F., Sakellariou G., Caprioli M., Montecucco C., Sarzi-Puttini P., Safety of tumor necrosis factor blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care and Research 2010 62 6 749 754 2-s2.0-77953102456 10.1002/acr.20130
49. Atzeni F., Sarzi-Puttini P., Mutti A., Bugatti S., Cavagna L., Caporali R., Long-term safety of abatacept in patients with rheumatoid arthritis. Autoimmunity Reviews 2013 12 12 1115 1117
50. Caporali R., Caprioli M., Bobbio-Pallavicini F., Bugatti S., Montecucco C., Long term treatment of rheumatoid arthritis with rituximab. Autoimmunity Reviews 2009 8 7 591 594 2-s2.0-67349120767 10.1016/j.autrev.2009.02.008
51. Md Yusof M. Y., Emery P., Targeting interleukin-6 in rheumatoid arthritis. Drugs 2013 73 4 341 356 10.1007/s40265-013-0018-2
52. Singh J. A., Furst D. E., Bharat A., Curtis J. R., Kavanaugh A. F., Kremer J. M., Moreland L. W., O'Dell J., Winthrop K. L., Beukelman T., Bridges S. L. Jr., Chatham W. W., Paulus H. E., Suarez-Almazor M., Bombardier C., Dougados M., Khanna D., King C. M., Leong A. L., Matteson E. L., Schousboe J. T., Moynihan E., Kolba K. S., Jain A., Volkmann E. R., Agrawal H., Bae S., Mudano A. S., Patkar N. M., Saag K. G., 2012 update of the 2008 American college of rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care and Research 2012 64 5 635 639 2-s2.0-84859832981 10.1002/acr.21641
53. Smolen J. S., Landewé R., Breedveld F. C., EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Annals of the Rheumatic Diseases 2014 73 492 509 10.1136/annrheumdis-2013-204573
54. Caporali R., Conti F., Alivernini S., Atzeni F., Seriolo B., Cutolo M., Valesini G., Ferraccioli G., Sarzi-Puttini P., Salvarani C., Guiducci S., Zampogna G., Gremese E., Pipitone N., Scrivo R., Bugatti S., Montecucco C., Matucci-Cerinic M., Italian Society for Rheumatology I. S. F. R., Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy. Clinical and Experimental Rheumatology 2011 29 3 S7 S14 2-s2.0-80055068987
55. Caporali R., Pallavicini F. B., Filippini M., Gorla R., Marchesoni A., Favalli E. G., Sarzi-Puttini P., Atzeni F., Montecucco C., Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal. Autoimmunity Reviews 2009 8 3 274 280 2-s2.0-58749116632 10.1016/j.autrev.2008.11.003
56. Sorenson C., Naci H., Cylus J., Mossialos E., Evidence of comparative efficacy should have a formal role in European drug approvals. British Medical Journal 2011 343 d4849 2-s2.0-84857426558
57. Sox H. C., Goodman S. N., The methods of comparative effectiveness research. Annual Review of Public Health 2012 33 425 445 10.1146/annurev- publhealth-031811-124610
58. Glenny A. M., Altman D. G., Song F., Sakarovitch C., Deeks J. J., D'Amico R., Bradburn M., Eastwood A. J., Indirect comparisons of competing interventions. Health Technology Assessment 2005 9 26 1 148 2-s2.0-21244495516
59. Caldwell D. M., Ades A. E., Higgins J. P. T., Simultaneous comparison of multiple treatments: combining direct and indirect evidence. British Medical Journal 2005 331 7521 897 900 2-s2.0-26944454062
60. Bucher H. C., Guyatt G. H., Griffith L. E., Walter S. D., The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. Journal of Clinical Epidemiology 1997 50 6 683 691 2-s2.0-0030793120 10.1016/S0895-4356(97)00049-8
61. Cipriani A., Higgins J. P., Geddes J. R., Salanti G., Conceptual and technical challenges in network meta-analysis.,Annals of Internal Medicine 2013 159 2 130 137 10.7326/0003-4819-159-2-201307160-00008
62. Jansen J. P., Crawford B., Bergman G., Stam W., Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value in Health 2008 11 5 956 964 2-s2.0-52649100566 10.1111/j.1524-4733.2008. 00347.x
63. Kass R. E., Statistical inference: the big picture. Statistical Science 2011 26 1 1 9 2-s2.0-82955235039 10.1214/10-STS337
64. Song F., Xiong T., Parekh-Bhurke S., Loke Y. K., Sutton A. J., Eastwood A. J., Holland R., Chen Y.-F., Glenny A.-M., Deeks J. J., Altman D. G., Inconsistency between direct and indirect comparisons of competing interventions: meta-epidemiological study. British Medical Journal 2011 343 d4909 2-s2.0-84859007944 10.1136/bmj.d4909
65. Singh J. A., Cameron D. R., Summary of AHRQ's comparative effectiveness review of drug therapy for rheumatoid arthritis (RA) in adults-an update. Journal of Managed Care Pharmacy 2012 18 4 S1 S18
66. Yazici Y., Long-term safety of Methotrexate in the treatment of rheumatoid arthritis. Clinical and Experimental Rheumatology 2010 28 5 S65 S67 2-s2.0-78650527357
67. Singh J. A., Christensen R., Wells G. A., Suarez-Almazor M. E., Buchbinder R., Lopez-Olivo M. A., Ghogomu E. T., Tugwell P., A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. Canadian Medical Association Journal 2009 181 11 787 796 2-s2.0-72949116165 10.1503/cmaj.091391
68. Schmitz S., Adams R., Walsh C. D., Barry M., FitzGerald O., A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach. Annals of the Rheumatic Diseases 2012 71 2 225 230 2-s2.0-84855352586 10.1136/annrheumdis-2011-200228
69. Thorlund K., Druyts E., Aviña-Zubieta J. A., Wu P., Mills E. J., Why the findings of published multiple treatment comparison meta-analyses of biologic treatments for rheumatoid arthritis are different: an overview of recurrent methodological shortcomings. Annals of the Rheumatic Diseases 2013 72 9 1524 1535 10.1136/annrheumdis-2012-201574
70. Favalli E. G., Pregnolato F., Biggioggero M., Meroni P. L., The comparison of effects of biologic agents on rheumatoid arthritis damage progression is biased by period of enrolment: data from a systematic review and meta-analysis. Seminars in Arthritis and Rheumatism 2013 10.1016/j.semarthrit. 2013.11.006
71. Lillie E. O., Patay B., Diamant J., Issell B., Topol E. J., Schork N. J., The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? Personalized Medicine 2011 8 2 161 173 2-s2.0-79952590347 10.2217/pme.11.7
72. Zucker D. R., Schmid C. H., McIntosh M. W., D'Agostino R. B., Selker H. P., Lau J., Combining single patient (N-of-1) trials to estimate population treatment effects and to evaluate individual patient responses to treatment. Journal of Clinical Epidemiology 1997 50 4 401 410 2-s2.0-0030913882 10.1016/S0895-4356(96)00429-5
73. Yelland M. J., Nikles C. J., McNairn N., del Mar C. B., Schluter P. J., Brown R. M., Celecoxib compared with sustained-release paracetamol for osteoarthritis: a series of n-of-1 trials. Rheumatology 2007 46 1 135 140 2-s2.0-33845585435 10.1093/rheumatology/kel195
74. Campbell M. K., Piaggio G., Elbourne D. R., Altman D. G., Consort 2010 statement: extension to cluster randomised trials. British Medical Journal 2012 345 e5661
75. Fransen J., Moens H. B., Speyer I., van Riel P. L. C. M., Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial. Annals of the Rheumatic Diseases 2005 64 9 1294 1298 2-s2.0-23944447850 10.1136/ard.2004. 030924
76. Schwartz D., Lellouch J., Explanatory and pragmatic attitudes of therapeutical trials. Journal of Clinical Epidemiology 2009 62 5 499 505 2-s2.0-63649136121 10.1016/j.jclinepi.2009.01.012
77. Thorpe K. E., Zwarenstein M., Oxman A. D., Treweek S., Furberg C. D., Altman D. G., Tunis S., Bergel E., Harvey I., Magid D. J., Chalkidou K., A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. Journal of Clinical Epidemiology 2009 62 5 464 475 2-s2.0-63449090101 10.1016/j.jclinepi.2008.12.011
78. Goekoop-Ruiterman Y. P. M., de Vries-Bouwstra J. K., Allaart C. F., van Zeben D., Kerstens P. J. S. M., Hazes J. M. W., Zwinderman A. H., Ronday H. K., Han K. H., Westedt M. L., Gerards A. H., van Groenendael J. H. L. M., Lems W. F., van Krugten M. V., Breedveld F. C., Dijkmans B. A. C., Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the best study): a randomized, controlled trial. Arthritis and Rheumatism 2005 52 11 3381 3390 2-s2.0-27744514865 10.1002/art.21405
79. Klarenbeek N. B., Güler-Yüksel M., van der Kooij S. M., Han K. H., Ronday H. K., Kerstens P. J. S. M., Seys P. E. H., Huizinga T. W. J., Dijkmans B. A. C., Allaart C. F., The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Annals of the Rheumatic Diseases 2011 70 6 1039 1046 2-s2.0-79955856735 10.1136/ard.2010.141234
80. Kairalla J. A., Coffey C. S., Thomann M. A., Muller K. E., Adaptive trial designs: a review of barriers and opportunities. Trials 2012 13 145
81. Chow S. C., Adaptive clinical trial design. Annual Review of Medicine 2014 65 405 415 10.1146/annurev-med-092012-112310
82. Vandemeulebroecke M., Group sequential and adaptive designs-a review of basic concepts and points of discussion. Biometrical Journal 2008 50 4 541 557 2-s2.0-54349106124 10.1002/bimj.200710436
83. Dahabreh I. J., Terasawa T., Castaldi P. J., Trikalinos T. A., Systematic review: anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Annals of Internal Medicine 2011 154 1 37 49 2-s2.0-79551580551
84. Freidlin B., McShane L. M., Korn E. L., Randomized clinical trials with biomarkers: design issues. Journal of the National Cancer Institute 2010 102 3 152 160 2-s2.0-76349100026 10.1093/jnci/djp477
85. Dienstmann R., Rodon J., Tabernero J., Biomarker-driven patient selection for early clinical trials. Current Opinion in Oncology 2013 25 3 305 312
86. Willemze A., Trouw L. A., Toes R. E. M., Huizinga T. W. J., The influence of ACPA status and characteristics on the course of RA. Nature Reviews Rheumatology 2012 8 3 144 152 2-s2.0-84857922958 10.1038/nrrheum.2011.204
87. van Aken J., Heimans L., Gillet-van Dongen H., Five-year outcomes of probable rheumatoid arthritis treated with methotrexate or placebo during the first year (the PROMPT study). Annals of the Rheumatic Diseases 2014 73 2 396 400 10.1136/annrheumdis-2012-202967
88. Olivieri I., Sarzi-Puttini P., Bugatti S., Atzeni F., d'Angelo S., Caporali R., Early treatment in early undifferentiated arthritis. Autoimmunity Reviews 2012 11 8 589 592 2-s2.0-80455168146 10.1016/j.autrev.2011.10.019
89. Bugatti S., Manzo A., Caporali R., Montecucco C., Assessment of synovitis to predict bone erosions in rheumatoid arthritis. Therapeutic Advances in Musculoskeletal Disease 2012 4 4 235 244 10.1177/1759720X12453092
90. Bugatti S., Manzo A., Bombardieri M., Vitolo B., Humby F., Kelly S., Montecucco C., Pitzalis C., Synovial tissue heterogeneity and peripheral blood biomarkers. Current Rheumatology Reports 2011 13 5 440 448 2-s2.0-80755172249 10.1007/s11926-011-0201-y
91. Reynisdottir G., Karimi R., Joshua V., Structural lung changes and local anti-citrulline immunity are early features of anti citrullinated-proteins antibodies positive rheumatoid arthritis. Arthritis and Rheumatology 2013 66 1 31 39 10.1002/art.38201
92. Manzo A., Caporali R., Vitolo B., Alessi S., Benaglio F., Todoerti M., Bugatti S., Calliada F., Montecucco C., Subclinical remodelling of draining lymph node structure in early and established rheumatoid arthritis assessed by power Doppler ultrasonography. Rheumatology 2011 50 8 1395 1400 2-s2.0-84855735731
93. Bugatti S., Manzo A., Caporali R., Montecucco C., Inflammatory lesions in the bone marrow of rheumatoid arthritis patients: a morphological perspective. Arthritis Research & Therapy 2012 14 6, article 229
94. Bugatti S., Manzo A., Benaglio F., Klersy C., Vitolo B., Todoerti M., Sakellariou G., Montecucco C., Caporali R., Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power Doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying anti-rheumatic drugs. Arthritis Research & Therapy 2012 14 1, article R34 2-s2.0-84856979170 10.1186/ar3742
95. Siebuhr A. S., Bay-Jensen A. C., Leeming D. J., Serological identification of fast progressors of structural damage with rheumatoid arthritis. Arthritis Research & Therapy 2013 15 4, article R86
96. Ponchel F., Goëb V., Parmar R., An immunological biomarker to predict MTX response in early RA. Annals of the Rheumatic Diseases 2013 4 4 235 244 10.1136/annrheumdis-2013-203566
97. Meyer M., Sellam J., Fellahi S., Serum level of adiponectin is a surrogate independent biomarker of radiographic disease progression in early rheumatoid arthritis: results from the ESPOIR cohort. Arthritis Research & Therapy 2013 15 6, article R210
98. Scirè C., Epis O., Codullo V., Humby F., Morbini P., Manzo A., Caporali R., Pitzalis C., Montecucco C., Immunohistological assessment of the synovial tissue in small joints in rheumatoid arthritis: validation of a minimally invasive ultrasound-guided synovial biopsy procedure. Arthritis Research & Therapy 2007 9 5, article R101 2-s2.0-36448962702 10.1186/ar2302
99. Haringman J. J., Gerlag D. M., Zwinderman A. H., Smeets T. J. M., Kraan M. C., Baeten D., McInnes I. B., Bresnihan B., Tak P. P., Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 2005 64 6 834 838 2-s2.0-19544374324 10.1136/ard.2004.029751
100. Bugatti S., Manzo A., Vitolo B., High expression levels of the B cell chemoattractant CXCL13 in rheumatoid synovium are a marker of severe disease. Rheumatology 2014
101. European Agency for the Evaluation of Medicinal Products, Points to consider on clinical investigation of medicinal products other than Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) for the treatment of rheumatoid arthritis. 2003, http://www.ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2009/09/WC500003439.pdf
102. Estellat C., Ravaud P., Lack of head-to-head trials and fair control arms: randomized controlled trials of biologic treatment for rheumatoid arthritis. Archives of Internal Medicine 2012 172 3 237 244 2-s2.0-84857410587 10.1001/archinternmed.2011.1209
103. Smolen J. S., Boers M., Abadie E. C., Breedveld F. C., Emery P., Bardin T., Goel N., Ethgen D. J., Avouac B. P., Dere W. H., Durez P., Matucci-Cerinic M., Flamion B., Laslop A., Lekkerkerker F. J., Miossec P., Mitlak B. H., Ormarsdttir S., Paolozzi L., Rao R., Reiter S., Tsouderos Y., Reginster J.-Y., Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA. Current Medical Research and Opinion 2011 27 2 315 325 2-s2.0-78651383189 10.1185/03007995.2010. 542135
104. Streiner D. L., Alternatives to placebo-controlled trials. Canadian Journal of Neurological Sciences 2007 34 1 S37 S41 2-s2.0-34248598459
105. Lesaffre E., Superiority, equivalence, and non-inferiority trials. Bulletin of the NYU Hospital for Joint Diseases 2008 66 2 150 154 2-s2.0-46049100805
106. Weinblatt M. E., Kaplan H., Germain B. F., Merriman R. C., Solomon S. D., Wall B., Anderson L., Block S., Irby R., Wolfe F., Gall E., Torretti D., Biundo J., Small R., Coblyn J., Polisson R., Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis. A thirty-six-week, double-blind trial. Arthritis and Rheumatism 1990 33 3 330 338 2-s2.0-0025318811
107. Williams H. J., Ward J. R., Reading J. C., Brooks R. H., Clegg D. O., Skosey J. L., Weisman M. H., Willkens R. F., Singer J. Z., Alarcon G. S., Field E. H., Clements P. J., Russell I. J., Hochman R. F., Boumpas D. T., Marble D. A., Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis and Rheumatism 1992 35 3 259 269 2-s2.0-0026579862
108. Jeurissen M. E. C., Boerbooms A. M. T., van de Putte L. B. A., Doesburg W. H., Mulder J., Rasker J. J., Kruijsen M. W. M., Haverman J. F., Van Beusekom H. J., Muller W. H., Franssen M. J. A. M., De Rooy D.-J. R. A. M., Methotrexate versus azathioprine in the treatment of rheumatoid arthritis: a forty-eight-week randomized, double-blind trial. Arthritis and Rheumatism 1991 34 8 961 972 2-s2.0-0025912605
109. Jeurissen M. E. C., Boerbooms A. M. T., van de Putte L. B. A., Doesburg W. H., Lemmens A. M., Influence of methotrexate and azathioprine on radiologic progression in rheumatoid arthritis: a randomized, double-blind study. Annals of Internal Medicine 1991 114 12 999 1004 2-s2.0-0026425142
110. Willkens R. F., Sharp J. T., Stablein D., Marks C., Wortmann R., Comparison of azathioprine, methotrexate, and the combination of the two in the treatment of rheumatoid arthritis: a forty-eight-week controlled clinical trial with radiologic outcome assessment. Arthritis and Rheumatism 1995 38 12 1799 1806 2-s2.0-0029566876 10.1002/art.1780381213
111. Drosos A. A., Voulgari P. V., Papadopoulos I. A., Politi E. N., Georgiou P. E., Zikou A. K., Cyclosporine A in the treatment of early rheumatoid arthritis. A prospective, randomized 24-month study. Clinical and Experimental Rheumatology 1998 16 6 695 701 2-s2.0-0031791048
112. Ferraccioli G. F., Gremese E., Tomietto P., Favret G., Damato R., Di Poi E., Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years. Rheumatology 2002 41 8 892 898 2-s2.0-0036049943
113. Hamilton J., McInnes I. B., Thomson E. A., Porter D., Hunter J. A., Madhok R., Capell H. A., Comparative study of intramuscular gold and methotrexate in a rheumatoid arthritis population from a socially deprived area. Annals of the Rheumatic Diseases 2001 60 6 566 572 2-s2.0-0035003318 10.1136/ard.60.6.566
114. Rau R., Herborn G., Menninger H., Sangha O., Radiographic outcome after three years of patients with early erosive rheumatoid arthritis treated with intramuscular methotrexate or parenteral gold. Extension of a one-year double-blind study in 174 patients. Rheumatology 2002 41 2 196 204 2-s2.0-0036105568
115. Smolen J. S., Kalden J. R., Scott D. L., Rozman B., Kvien T. K., Larsen A., Loew-Friedrich I., Oed C., Rosenburg R., Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. The Lancet 1999 353 9149 259 266 2-s2.0-0033053835 10.1016/S0140-6736(98)09403-3
116. Strand V., Cohen S., Schiff M., Weaver A., Fleischmann R., Cannon G., Fox R., Moreland L., Olsen N., Furst D., Caldwell J., Kaine J., Sharp J., Hurley F., Loew-Friedrich I., Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Archives of Internal Medicine 1999 159 21 2542 2550 2-s2.0-0033596065 10.1001/archinte.159.21.2542
117. Cohen S. B., Cannon G. W., Schiff M. H., Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis and Rheumatism 2001 44 9 1984 1992
118. Strand V., Scott D. L., Emery P., Kalden J. R., Smolen J. S., Cannon G. W., Tugwell P., Crawford B., Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. Journal of Rheumatology 2005 32 4 590 601 2-s2.0-17144408362
119. Emery P., Breedveld F. C., Lemmel E. M., Kaltwasser J. P., Dawes P. T., Gömör B., Van Den Bosch F., Nordström D., Bjørneboe O., Dahl R., Hørslev-Petersen K., Rodriguez De La Serna A., Molloy M., Tikly M., Oed C., Rosenburg R., Loew-Friedrich I., A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology 2000 39 6 655 665 2-s2.0-6744262231
120. Bao C., Chen S., Gu Y., Lao Z., Ni L., Yu Q., Xu J., Li X., Liu J., Sun L., He P., Ma J., Xu S., Ding C., Leflunomide, a new disease-modifying drug for treating active rheumatoid arthritis in methotrexate-controlled phase II clinical trial. Chinese Medical Journal 2003 116 8 1228 1234 2-s2.0-0041328553
121. Haagsma C. J., van Riel P. L. C. M., de Jong A. J. L., van de Putte L. B. A., Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. British Journal of Rheumatology 1997 36 10 1082 1088 2-s2.0-0030696346
122. Dougados M., Combe B., Cantagrel A., Goupille P., Olive P., Schattenkirchner M., Meusser S., Paimela L., Rau R., Zeidler H., Leirisalo-Repo M., Peldan K., Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Annals of the Rheumatic Diseases 1999 58 4 220 225 2-s2.0-0032957015
123. Capell H. A., Madhok R., Porter D. R., Munro R. A. L., McInnes I. B., Hunter J. A., Steven M., Zoma A., Morrison E., Sambrook M., Fat W. P., Hampson R., McDonald F., Tierney A., Henderson N., Ford I., Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study. Annals of the Rheumatic Diseases 2007 66 2 235 241 2-s2.0-33846864259 10.1136/ard.2006.057133
124. Genovese M. C., Bathon J. M., Martin R. W., Fleischmann R. M., Tesser J. R., Schiff M. H., Keystone E. C., Wasko M. C., Moreland L. W., Weaver A. L., Markenson J., Cannon G. W., Spencer-Green G., Finck B. K., Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis and Rheumatism 2002 46 6 1443 1450 2-s2.0-0036274944 10.1002/art.10308
125. Jones G., Sebba A., Gu J., Lowenstein M. B., Calvo A., Gomez-Reino J. J., Siri D. A., Tomšič M., Alecock E., Woodworth T., Genovese M. C., Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Annals of the Rheumatic Diseases 2010 69 1 88 96 2-s2.0-73449118587 10.1136/ard.2008.105197
126. van Vollenhoven R. F., Fleischmann R. M., Cohen S. B., Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. The New England Journal of Medicine 2012 367 6 508 519 10.1056/NEJMoa1112072
127. Gabay C., Emery P., van Vollenhoven R. F., Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. The Lancet 2013 381 9877 1541 1550 10.1016/S0140-6736(13)60250-0
128. Weinblatt M. E., Schiff M. H., Valente R., Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study. Arthritis and Rheumatism 2013 65 1 28 38 10.1002/art.37711
129. Schiff M. H., Weinblatt M. E., Valente R., Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Annals of the Rheumatic Diseases 2014 73 1